News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

APP Pharmaceuticals Announces Approval and Launch of Clonidine Hydrochloride Injection


7/11/2011 9:58:48 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths. Clonidine Hydrochloride Injection is therapeutically equivalent to the reference-listed drug DuraclonĀ®, currently marketed by the innovator Astellas U.S. Holding, Inc. (formerly Yamanouchi U.S. Holding Inc.).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES